Midterm results of percutaneous transluminal coronary angioplasty in graft coronary artery disease in cardiac transplant patients

Marelli, Marina Montagnani; Rábago, Gregorio; Calabuig, J; Caro, D. Martínez; Coma-Canella, Isabel; Martín-Trenor, Alejandro

doi:10.1016/s0041-1345(99)00454-6

Cited by 7 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the denervation of the afferent cardiac nervous system and absence or incomplete reinnervation of the cardiac allograft, most heart transplant patients present asymptomatically, and if at all, with atypical angina (20), as is evidenced in our current study. Therefore, the first clinical manifestations of coronary allograft ischemia predominantly include congestive heart failure, ventricular arrhythmias, silent myocardial infarction, or sudden cardiac death (29). As such, given its asymptomatic nature and progressive nature of TCAV, close and frequent surveillance for heart transplant recipients is necessary.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous coronary intervention versus coronary artery bypass grafting in heart transplant recipients with coronary allograft vasculopathy: a systematic review and meta-analysis of 1,520 patients

Luc¹,

Choi²,

Rizvi³

et al. 2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

CABG and PCI are both feasible modalities for revascularization in patients with TCAV where PCI is associated with lower mortality. There were no differences in outcomes among patients who underwent PCI with DES as compared to BMS. Potential bias may exist due to heterogeneity in available data. Further studies are needed to delineate evidence-based guidelines to tailor the appropriate therapy, CABG or PCI, to the appropriate patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Percutaneous coronary intervention versus coronary artery bypass grafting in heart transplant recipients with coronary allograft vasculopathy: a systematic review and meta-analysis of 1,520 patients

Luc¹,

Choi²,

Rizvi³

et al. 2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

show abstract

“…Percutaneous transluminal coronary angioplasty (PTCA) has been commonly used for treatment of focal CAV lesions in proximal or mid coronary segments [137][138][139][140][141]. Overall results of PTCA approach those obtained in atherosclerotic lesions, with 97 -99% angiographic success, 0 -2.6% mortality and 25 -55% restenosis rate at 6 months.…”

Section: Treatment Of Established Cardiac Allograft Vasculopathymentioning

confidence: 99%

Treatment of allograft vasculopathy in heart transplantation

Segovia¹,

Gómez‐Bueno²,

Alonso‐Pulpón³

2006

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Cardiac allograft vasculopathy remains one of the main causes of morbidity and mortality after heart transplantation, although its impact is becoming somewhat smaller as prophylactic measures are implemented. Advances in the understanding of the molecular and cellular mechanisms involved in the genesis and development of cardiac allograft vasculopathy are opening ways for new diagnostic and therapeutic strategies. Successful prophylaxis of the early stages of the disease has been demonstrated with the use of newer immunosuppressive agents, such as sirolimus and everolimus, that will probably be included in future protocols. For most patients with established cardiac allograft vasculopathy, currently available revascularisation methods and retransplantation are not appropriate options. Antiproliferative agents could provide significant improvement in terms of symptom relief and prognosis, but their definite value must be proven in well-designed trials.

show abstract